T-cells stoop to conquer

In Person Only

Dr. Srivastava has been engaged in research and clinical studies in cancer immunology since 1980. He pioneered the use of personalized cancer vaccines for human cancer immunotherapy starting in 1994, and continuing through presently (see Srivastava, Scientific American, July 2008, for a general account). Dr. Srivastava obtained his bachelor’s degree in biology and chemistry and a master’s degree in botany (paleontology) from the University of Allahabad, India. He studied yeast genetics at Osaka University School of Engineering, Japan and completed his Ph.D. in biochemistry at the Center for Cellular and Molecular Biology, Hyderabad, India. He received his MD degree from the University of Connecticut and post-doctoral training at Yale University and Sloan-Kettering Institute for Cancer Research. He is widely published (~200 papers including in the most prestigious journals including Science, Nature Immunology, Science Immunology, Nature Reviews Immunology, Immunity, Journal of
Clinical Investigation, Journal of Experimental Medicine, Proceedings of US National Academy, Lancet, Journal of Clinical Oncology etc.) and is among the most highly cited authors in Immunology.

He has been a recipient of many awards, including the First Independent Research Support and Transition Award of NIH (1987), Irma T. Hirshl Award (1989), induction into the Roll of Honor of the UICC (Union Internationale Contre le cancer), election to the National Academy of Inventors (2016), Neag Medal of Honor (2016) from the University of Connecticut, the 2020 SITC Team Science Award, and election as a Fellow of American Association of Advancement of Sciences (2022). He is listed in a number of “Who’s Who”. He has had research support from the NIH over 35 years. He was a permanent member of the Experimental Immunology Study Section of the NIH (1994- 99) and serves on the Scientific Advisory Council of the Cancer Research Institute since 1995. He serves as a permanent member on the Immuno-Oncology study section of the NIH (2019 to 2023), and on the study section for NextGen Grants for Transformative Cancer Research of the American Association for Cancer Research (since 2018 to 2022). He has organized and convened a number of national and international conferences including co-chairing a Gordon Conference. He serves on the editorial board of a number of journals in immunology and cancer immunology, including as a Senior Editor of Cancer Immunology Research, a major journal of the American Association of Cancer Research, an editorial board member of Immunotherapy Advances, a journal of the British Society for Immunology, and a Reviewing Editor for eLife. He is an inventor on over a hundred awarded patents and has co-founded a number of biotechnology companies including a public company (NASDAQ: AGEN).